about
CYP51 structures and structure-based development of novel, pathogen-specific inhibitory scaffoldsDrug-induced liver injury: a clinical updateT-cell-mediated drug hypersensitivity: immune mechanisms and their clinical relevanceMicroRNAs in Drug-induced Liver InjuryIdiosyncratic adverse drug reactions: current conceptsDrug allergy: causes and desensitizationDrug hypersensitivity caused by alteration of the MHC-presented self-peptide repertoireMechanism-based inactivation of CYP450 enzymes: a case study of lapatinibExploring off-targets and off-systems for adverse drug reactions via chemical-protein interactome--clozapine-induced agranulocytosis as a case studyThe impact of duration of treatment on reported time-to-onset in spontaneous reporting systems for pharmacovigilanceMechanism of isoniazidāinduced hepatotoxicity: then and nowRelationships Between Pharmacovigilance, Molecular, Structural, and Pathway Data: Revealing Mechanisms for Immune-Mediated Drug-Induced Liver Injury.Adverse reactions to targeted and non-targeted chemotherapeutic drugs with emphasis on hypersensitivity responses and the invasive metastatic switch.Protein adducts as prospective biomarkers of nevirapine toxicity.Relationship between characteristics of medications and drug-induced liver disease phenotype and outcome.Synthesis and evaluation of indole-based chalcones as inducers of methuosis, a novel type of nonapoptotic cell death.Mechanisms of drug-induced liver injury: from bedside to bench.In silico analysis of HLA associations with drug-induced liver injury: use of a HLA-genotyped DNA archive from healthy volunteersZebrafish as model organisms for studying drug-induced liver injuryEvaluation of sulfonamide detoxification pathways in haematologic malignancy patients prior to intermittent trimethoprim-sulfamethoxazole prophylaxis.Metabolism-related pharmacokinetic drug-drug interactions with tyrosine kinase inhibitors: current understanding, challenges and recommendations.Synergistic drug-cytokine induction of hepatocellular death as an in vitro approach for the study of inflammation-associated idiosyncratic drug hepatotoxicity.Hepatic safety of antibiotics used in primary careRisk factors for idiosyncratic drug-induced liver injury.Schisandrin B inhibits cell growth and induces cellular apoptosis and autophagy in mouse hepatocytes and macrophages: implications for its hepatotoxicity.Amiodarone exposure during modest inflammation induces idiosyncrasy-like liver injury in rats: role of tumor necrosis factor-alpha.Molecular docking to identify associations between drugs and class I human leukocyte antigens for predicting idiosyncratic drug reactions.The clinical features of drug-induced liver injury observed through liver biopsy: focus on relevancy to autoimmune hepatitis.A comprehensive study of the association between drug hepatotoxicity and daily dose, liver metabolism, and lipophilicity using 975 oral medications.Glycocapture-assisted global quantitative proteomics (gagQP) reveals multiorgan responses in serum toxicoproteome.The plasma proteome, adductome and idiosyncratic toxicity in toxicoproteomics researchAssociation of human leukocyte antigen alleles and nevirapine hypersensitivity in a Malawian HIV-infected population.Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States.p38 mitogen-activated protein kinase-dependent tumor necrosis factor-alpha-converting enzyme is important for liver injury in hepatotoxic interaction between lipopolysaccharide and ranitidine.Role of biotransformation studies in minimizing metabolism-related liabilities in drug discovery.The nonenzymatic reactivity of the acyl-linked metabolites of mefenamic acid toward amino and thiol functional group bionucleophiles.Inflammatory stress and idiosyncratic hepatotoxicity: hints from animal models.Drug-induced liver injury: what was new in 2008?Drug-induced liver injury: insights from genetic studies.In vitro testing for the diagnosis of anticonvulsant hypersensitivity syndrome: a systematic review.
P2860
Q24605691-CE35DBF9-2DCF-47B2-ABF1-26DD04E6ABEEQ24617074-5974CC87-9722-4A64-888B-57004C277E9CQ26747638-4A11898B-A796-4BC2-A082-C18F6F56ECF4Q26781801-72DE804F-F954-46D1-80FC-B3A0C5C936FDQ26824391-A80563F1-AA91-45EC-8D16-82281C819D84Q27012238-17BF2E23-E5F3-46AF-9611-8817E961D52CQ27679355-EFC5BDE4-9160-4B76-B95B-39071434768BQ28080497-2EF6F49F-E4F9-409B-AC6A-FF03BAFEBF57Q28477582-55279985-A59B-47DF-96C3-DD646B78B535Q28534667-7D8C7B25-D1ED-4128-872C-3811CF37EC85Q29248263-450D48D7-C966-47B4-A274-D26FBE87B91EQ30990061-DD0A02D0-83B6-4A5A-95FD-EEA958A07C5CQ33410375-F98FAA48-C045-4BE2-921C-14C02CB131F0Q33681307-787F1371-A993-4934-8800-E06389B40349Q33784830-33042899-6535-4355-8D40-B4A911045250Q34159322-229F5BDE-058E-41F8-BE32-80F8B9E5AA5FQ34169362-E1A134F5-2E48-43C5-BB04-567DE743E605Q34316771-AB5ECEFE-9318-4DD8-888C-60FAF14D931CQ34450956-EC6137E4-77ED-442C-B2C6-4732D4E1ADFFQ34830063-2C71036C-C901-41CF-9784-83F47CB241B6Q35023711-F8762411-138C-413F-8CE5-84E3DC3F4B4FQ35026973-180A4CDD-FD03-47D1-9110-A1A87F48925FQ35037383-67F410BB-828A-4D45-8242-3A9F64C6EFA5Q35168108-CCFF4DCD-CB14-4BFE-B0BE-18E3D3ACB237Q35490308-C0C9DCC3-9478-4CD9-A8A4-62FFC3B3281BQ35626791-84C57EB0-259A-49CD-AFE9-116FB08065A5Q36089652-3FBEBD53-AA3E-4E3C-B56D-751B5CE42A21Q36153978-FB6C5A36-288B-4F2C-8E98-FEF29A15AED4Q36231948-8943AA8B-8513-40A7-8C83-BFD5AE3DA851Q36642297-34B0AD64-0BEC-4BB2-8BDB-3D5FE4539AB9Q36667345-7EBE6770-E6AE-4AB7-B139-98E0D52EE737Q36740238-E84A9179-552E-49FB-BF2E-3FCD856545C1Q36844723-3FDFAAB5-D2A7-4301-86B7-549B2C8664E6Q36862180-1F70811F-1C00-4E7F-9EB8-CA94AD30EDFDQ37150879-045B764D-D4EF-4E5F-BDE3-2FABAE2DB718Q37251999-11E94627-B17E-460D-8F93-D3726B1EFEE2Q37391731-E8128AF2-26FF-47F1-B2CF-F47EF9088E7FQ37510856-7E813027-1F55-497E-961C-04A157821282Q37598897-603CBDD0-8F02-4190-A35F-76BA355325F8Q37605792-381EEC12-2AFB-4E66-A5E9-C5BCE471D63E
P2860
description
2007 nĆ® lÅ«n-bĆ»n
@nan
2007幓ć®č«ę
@ja
2007幓č«ę
@yue
2007幓č«ę
@zh-hant
2007幓č«ę
@zh-hk
2007幓č«ę
@zh-mo
2007幓č«ę
@zh-tw
2007幓č®ŗę
@wuu
2007幓č®ŗę
@zh
2007幓č®ŗę
@zh-cn
name
Idiosyncratic drug reactions: current understanding.
@ast
Idiosyncratic drug reactions: current understanding.
@en
type
label
Idiosyncratic drug reactions: current understanding.
@ast
Idiosyncratic drug reactions: current understanding.
@en
prefLabel
Idiosyncratic drug reactions: current understanding.
@ast
Idiosyncratic drug reactions: current understanding.
@en
P1476
Idiosyncratic drug reactions: current understanding.
@en
P2093
Jack Uetrecht
P304
P356
10.1146/ANNUREV.PHARMTOX.47.120505.105150
P577
2007-01-01T00:00:00Z